Insulet Corp (PODD)
164.73
-1.53
(-0.92%)
USD |
NASDAQ |
Apr 18, 16:00
164.66
-0.07
(-0.04%)
After-Hours: 20:00
Insulet Revenue (Quarterly): 509.80M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 509.80M |
| September 30, 2023 | 432.70M |
| June 30, 2023 | 396.50M |
| March 31, 2023 | 358.10M |
| December 31, 2022 | 369.70M |
| September 30, 2022 | 340.80M |
| June 30, 2022 | 299.40M |
| March 31, 2022 | 295.40M |
| December 31, 2021 | 307.70M |
| September 30, 2021 | 275.60M |
| June 30, 2021 | 263.20M |
| March 31, 2021 | 252.30M |
| December 31, 2020 | 246.10M |
| September 30, 2020 | 234.00M |
| June 30, 2020 | 226.30M |
| March 31, 2020 | 198.00M |
| December 31, 2019 | 209.40M |
| September 30, 2019 | 192.10M |
| June 30, 2019 | 177.10M |
| March 31, 2019 | 159.60M |
| December 31, 2018 | 164.88M |
| September 30, 2018 | 151.08M |
| June 30, 2018 | 124.26M |
| March 31, 2018 | 123.58M |
| December 31, 2017 | 130.56M |
| Date | Value |
|---|---|
| September 30, 2017 | 121.78M |
| June 30, 2017 | 109.76M |
| March 31, 2017 | 101.71M |
| December 31, 2016 | 103.58M |
| September 30, 2016 | 94.87M |
| June 30, 2016 | 87.33M |
| March 31, 2016 | 81.21M |
| December 31, 2015 | 83.80M |
| September 30, 2015 | 71.39M |
| June 30, 2015 | 60.55M |
| March 31, 2015 | 48.15M |
| December 31, 2014 | 15.16M |
| September 30, 2014 | 74.98M |
| June 30, 2014 | 72.01M |
| March 31, 2014 | 69.16M |
| December 31, 2013 | 68.53M |
| September 30, 2013 | 61.10M |
| June 30, 2013 | 60.09M |
| March 31, 2013 | 57.36M |
| December 31, 2012 | 57.83M |
| September 30, 2012 | 54.75M |
| June 30, 2012 | 51.04M |
| March 31, 2012 | 47.75M |
| December 31, 2011 | 47.19M |
| September 30, 2011 | 44.59M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
177.10M
Minimum
Jun 2019
509.80M
Maximum
Dec 2023
293.91M
Average
275.60M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Abbott Laboratories | 10.24B |
| Stryker Corp | 5.815B |
| Becton Dickinson & Co | 4.706B |
| Haemonetics Corp | 336.25M |
| Tandem Diabetes Care Inc | 196.80M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 103.30M |
| Total Expenses (Quarterly) | 403.40M |
| EPS Diluted (Quarterly) | 1.44 |
| Enterprise Value | 12.23B |
| Gross Profit Margin (Quarterly) | 70.85% |
| Profit Margin (Quarterly) | 20.26% |
| Earnings Yield | 1.77% |
| Operating Earnings Yield | 1.79% |
| Normalized Earnings Yield | 1.766 |